Clathrin differentially adapts its trimerisation domain during mammalian evolution to traffic the insulin-responsive GLUT4 glucose transporter.

Every time you eat, your body faces a vital task: moving sugar from your bloodstream into your muscles to be used for energy. This process relies on a specific gateway, a protein called GLUT4, which sits inside muscle cells waiting for a signal. When insulin arrives, it tells these cells to bring GLUT4 to the surface, opening the door so glucose can enter. Without this mechanism, sugar builds up in the blood, leading to metabolic problems. For decades, scientists have known that a cellular machine called clathrin helps move these gateways around, but the details of how this works in different animals have remained a puzzle. Some mammals, including humans, use a specialized version of this machine to handle the job, while other vertebrates seem to have lost the gene for that specific version entirely. The question has been how these animals manage the same essential task without the tool that humans rely on.

Researchers have now uncovered the solution to this evolutionary mystery by looking closely at how cells adapt when a key component is missing. In humans, a specific type of clathrin, known as CHC22, acts as the primary manager for moving GLUT4 in skeletal muscle. However, certain lineages of vertebrates have completely lost the gene that makes CHC22. The new study shows that these animals do not simply abandon the task; instead, they have evolved a clever workaround using a different, more common version of the clathrin machine. This universal version, called CHC17, usually handles general traffic within cells, but in species without CHC22, the cells produce a modified, shortened version of it. This special variant, which the researchers call CHC17-SAS, appears mostly in skeletal muscle and has a truncated end that looks very similar to the human CHC22.

To understand how this substitute works, the team examined the physical structure of the proteins. They determined the precise three-dimensional shape of the part of CHC22 responsible for holding three protein strands together, a section known as the trimerisation domain. The structure revealed that while the core shape is conserved from the universal CHC17, the surface electrical charge is different. This subtle change in charge allows the human CHC22 to bind to a specific helper protein called SNX5, which is essential for its unique role in glucose transport. The study found that the shortened CHC17-SAS found in other species acts as a functional surrogate for CHC22, enabling the same intracellular function. When the researchers tested this in human cells using GLUT4 translocation assays, they confirmed that CHC17-SAS could successfully take over the job of moving GLUT4, proving it is a functional replacement in this model system.

This discovery resolves a long-standing confusion about how different animals regulate their blood sugar. It shows that while the specific genetic tools may vary, the underlying strategy for managing glucose transport remains consistent across mammals. Whether an animal uses the specialized CHC22 or the adapted CHC17-SAS, the goal is the same: to ensure that glucose transporters reach the cell surface when insulin signals that it is time to eat. By identifying this alternative pathway, the research clarifies that the ability to traffic GLUT4 is a fundamental requirement for mammalian life, one that nature has solved through different but equally effective molecular designs.